Barlesi, F., Lolkema, M., Rohrberg, K. S., Hierro, C., Marabelle, A., Razak, A. A., Teixeira, L., Boni, V., Miller, W. H., Aggarwal, C., Stern, M., Cirovic, O., Cirovic, O., Romagnoli, B., Christen, R., Dodia, R., Smart, K., Reis, B., Staedler, N., Watson, C., & Steeghs, N. (n.d.). 291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors. Journal for immunotherapy of cancer, 8, A178. http://access.bl.uk/ark:/81055/vdc_100144723771.0x000004